Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 3/2020

01-12-2020 | Metastasis | ASO Author Reflections

ASO Author Reflection: Systemic Pharmacokinetics of Pressurized Intraperitoneal Aerosol Chemotherapy with Oxaliplatin in Patients with Colorectal Peritoneal Metastases

Authors: R. J. Lurvink, MD, K. P. Rovers, MD, I. H. J. T. de Hingh, MD, PhD, M. J. Deenen, PharmD, PhD

Published in: Annals of Surgical Oncology | Special Issue 3/2020

Login to get access

Excerpt

Pressurized intraperitoneal aerosol chemotherapy (PIPAC) is a laparoscopic method for repetitive intraperitoneal administration of low-dose chemotherapy as a pressurized aerosol, claiming homogeneous intraperitoneal drug distribution, deep direct tumor penetration, and low systemic chemotherapy exposure.1 Patients with colorectal peritoneal metastases most commonly receive PIPAC with oxaliplatin in a dose of 92 mg/m2 every 6 to 8 weeks.2,3 In addition, electrostatic precipitation of the aerosol is practiced in some centers, as this might further enhance tumor penetration.4 Although extensively described after intravenous administration5 and after hyperthermic intraperitoneal chemotherapy,6 the systemic pharmacokinetics of oxaliplatin after administration by PIPAC have never been investigated in humans. …
Literature
1.
Solass W, Kerb R, Murdter T, et al. Intraperitoneal chemotherapy of peritoneal carcinomatosis using pressurized aerosol as an alternative to liquid solution: first evidence for efficacy. Ann Surg Oncol. 2014;21(2):553–9.CrossRef
2.
Alyami M, Hübner M, Grass F, et al. Pressurised intraperitoneal aerosol chemotherapy: rationale, evidence, and potential indications. Lancet Oncol. 2019;20:e368–377.CrossRef
3.
Nowacki M, Alyami M, Villeneuve L, et al. Multicenter comprehensive methodological and technical analysis of 832 pressurized intraperitoneal aerosol chemotherapy (PIPAC) interventions performed in 349 patients for peritoneal carcinomatosis treatment: an international survey study. Eur J Surg Oncol. 2018;44:991–996.CrossRef
4.
Kakchekeeva T, Demtröder C, Herath NI, et al. In vivo feasibility of electrostatic precipitation as an adjunct to pressurized intraperitoneal aerosol chemotherapy (ePIPAC). Ann Surg Oncol. 2016;23(Suppl 5):592–598.CrossRef
5.
Graham MA, Lockwood GF, Greenslade D, et al. Clinical pharmacokinetics of oxaliplatin: a critical review. Clin Cancer Res. 2000;6:1205–18.PubMed
6.
Elias D, Bonnay M, Puizillou JM, et al. Heated intra-operative intraperitoneal oxaliplatin after complete resection of peritoneal carcinomatosis: pharmacokinetics and tissue distribution. Ann Oncol. 2002;13(2):267–72.CrossRef
7.
Lurvink RJ, Tajzai R, Rovers KP, et al. Systemic pharmacokinetics of oxaliplatin after intraperitoneal administration by electrostatic pressurized intraperitoneal aerosol chemotherapy (ePIPAC) in patients with unresectable colorectal peritoneal metastases in the CRC-PIPAC trial. Ann Surg Oncol. 2020. https://​doi.​org/​10.​1245/​s10434-020-08743-9.
Metadata
Title
ASO Author Reflection: Systemic Pharmacokinetics of Pressurized Intraperitoneal Aerosol Chemotherapy with Oxaliplatin in Patients with Colorectal Peritoneal Metastases
Authors
R. J. Lurvink, MD
K. P. Rovers, MD
I. H. J. T. de Hingh, MD, PhD
M. J. Deenen, PharmD, PhD
Publication date
01-12-2020
Publisher
Springer International Publishing
Published in
Annals of Surgical Oncology / Issue Special Issue 3/2020
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-020-08780-4

Other articles of this Special Issue 3/2020

Annals of Surgical Oncology 3/2020 Go to the issue

ASO Author Reflections

ASO Author Reflections: Which Patients with Invasive Intraductal Papillary Mucinous Neoplasm Can Benefit from Adjuvant Therapy?

Health Services Research and Global Oncology

Virtual Surgical Fellowship Recruitment During COVID-19 and Its Implications for Resident/Fellow Recruitment in the Future

ASO Visual Abstract

ASO Visual Abstract: Does Ipsilateral Cancer Increase Atypical Ductal Hyperplasia Upgrade?

ASO Author Reflections

ASO Author Reflections: Remote Home Monitoring After Surgery: Focus on Feasibility for Older Cancer Patients

ASO Author Reflections

ASO Author Reflections: Transdiaphragmatic Approach for Simultaneous Resection of Colorectal Liver and Lung Metastases

ASO Author Reflections

ASO Author Reflections: Conversion During Attempted Minimally Invasive Adrenalectomy for Adrenocortical Carcinoma: A Cautionary Tale